Salbutamol dry-powder inhalation - Dura/Spiros

Drug Profile

Salbutamol dry-powder inhalation - Dura/Spiros

Alternative Names: Albuterol dry-powder inhalation - Dura/Spiros; Albuterol Spiros

Latest Information Update: 02 Oct 2000

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Dura Pharmaceuticals
  • Developer Dura Pharmaceuticals; Spiros Development Corporation II
  • Class Antiasthmatics; Antibronchitics; Bronchodilators; Ethanolamines; Phenethylamines; Small molecules; Tocolytics
  • Mechanism of Action Beta 2 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Asthma

Most Recent Events

  • 02 Oct 2000 Discontinued-preregistration for Asthma in USA (Inhalation)
  • 07 Mar 2000 Dura announces intention to acquire Spiros Development Corporation II and discontinue development of Albuterol SpirosTM
  • 09 Dec 1999 A study in asthmatic patients has been added to the therapeutic trials section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top